Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a phase II, randomized, placebo‐controlled trial - van Vollenhoven, R. F.; Kinnman, N.; Vincent, E.; Wax, S.; Bathon, J. (Arthritis & rheumatology (Hoboken, N.J.), 2011)
Keywords: Adult; Aged; Antirheumatic Agents - adverse effects; Antirheumatic Agents - therapeutic use; Arthritis, Rheumatoid - drug therapy; Biological and medical sciences; Bones, joints and connective tissue. Antiinflammatory agents; Diseases of the osteoarticular system; Double-Blind Method; Drug therapy; Female; Flow Cytometry; Humans; Immunomodulators; Inflammatory joint diseases; Intention to Treat Analysis; Male; Medical sciences; Methotrexate; Methotrexate - adverse effects; Methotrexate - therapeutic use; Middle Aged; Odds Ratio; Pharmacology. Drug treatments; Recombinant Fusion Proteins - adverse effects; Recombinant Fusion Proteins - therapeutic use; Response rates; Rheumatoid arthritis; Treatment Outcome; Antineoplastic agent; Human; Immunopathology; Diseases of the osteoarticular system; Rheumatology; Autoimmune disease; Inflammatory joint disease; Atacicept; Immunomodulator; Chronic; Rheumatoid arthritis; Phase II trial; Antirheumatic agent; Methotrexate